Novocure (NVCR) Trading 7.3% Higher
Novocure Ltd (NASDAQ:NVCR)’s share price traded up 7.3% on Friday . The company traded as high as $53.00 and last traded at $52.91. 686,283 shares were traded during mid-day trading, an increase of 6% from the average session volume of 649,390 shares. The stock had previously closed at $49.31.
A number of equities analysts have recently weighed in on the stock. ValuEngine downgraded shares of Novocure from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. BidaskClub raised shares of Novocure from a “hold” rating to a “buy” rating in a research note on Wednesday, May 15th. Zacks Investment Research raised shares of Novocure from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Mizuho reaffirmed a “buy” rating and issued a $63.00 price target on shares of Novocure in a research note on Thursday, March 7th. Finally, SunTrust Banks assumed coverage on shares of Novocure in a research note on Tuesday, March 19th. They issued a “hold” rating and a $50.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $49.63.
The company has a debt-to-equity ratio of 1.27, a quick ratio of 4.39 and a current ratio of 4.73. The company has a market capitalization of $5.07 billion, a price-to-earnings ratio of -76.68 and a beta of 3.04.
In related news, CEO Asaf Danziger sold 903 shares of the company’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $54.40, for a total value of $49,123.20. Following the completion of the sale, the chief executive officer now directly owns 233,757 shares in the company, valued at $12,716,380.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gabriel Leung sold 5,000 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $49.79, for a total transaction of $248,950.00. The disclosure for this sale can be found here. Insiders sold 318,778 shares of company stock valued at $16,084,435 over the last quarter. 5.60% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of NVCR. PRW Wealth Management LLC bought a new stake in Novocure in the fourth quarter worth $36,000. NumerixS Investment Technologies Inc bought a new stake in Novocure in the fourth quarter worth $59,000. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Novocure by 35.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,331 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 349 shares in the last quarter. QS Investors LLC bought a new stake in Novocure during the fourth quarter valued at about $70,000. Finally, Fifth Third Bancorp boosted its holdings in Novocure by 66.0% during the first quarter. Fifth Third Bancorp now owns 1,454 shares of the medical equipment provider’s stock valued at $70,000 after acquiring an additional 578 shares during the period. Hedge funds and other institutional investors own 61.76% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Novocure (NVCR) Trading 7.3% Higher” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.dailypolitical.com/2019/05/26/novocure-nvcr-trading-7-3-higher.html.
Novocure Company Profile (NASDAQ:NVCR)
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline.
Read More: Limitations of the P/E Growth ratio
Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.